The company discontinued developing emugrobart after two studies showed the drug didn’t achieve intended outcomes.
Stocktwits on MSN
SRPT stock clocks highest daily gain in nearly 8 years after rare muscle disorders study data but Wall Street's not wholly convinced
Oppenheimer analyst Kostas Biliouris, meanwhile, said Sarepta's data in the programs "appear promising." ・The firm now awaits ...
Spinal and Bulbar Muscular Atrophy (SBMA) is a rare inherited disease that causes progressive muscle weakness and wasting in ...
The big pharma company will no longer progress emugrobart to late-stage trials in FSHD and SMA due to a lack of efficacy.
Sarepta (SRPT) stock rises on positive Phase 1/2 siRNA trial data showing muscle delivery, biomarker activity, and safety in ...
Muscle ultrasound has emerged as a pivotal, non‐invasive imaging modality that offers real‐time insights into muscle structure and pathology. This technique enables both qualitative and quantitative ...
Biomedical engineers have grown muscles in a lab to better understand and test treatments for a group of extremely rare muscle disorders called dysferlinopathy or limb girdle muscular dystrophies 2B ...
Researchers have made a significant finding in determining the genetic background of dilated cardiomyopathy in Dobermanns. This research helps us understand the genetic risk factors related to fatal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results